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 Intracerebral hemorrhage defines a category of neurological disease that spans the full 
range of possible clinical outcomes. At one end of the spectrum is hemorrhagic stroke, an 
oftendebilitating neurologic condition with substantial morbidity and mortality while cerebral 
microhemorrhage at the other end of the spectrum can go completely unnoticed as they are often 
asymptomatic. Despite the distinct clinical outcomes both conditions share a common risk factor, 
uncontrolled hypertension. Here we set out to generate a novel mouse model of intracerebral 
hemorrhage with pressure as the mode of hemorrhage induction. To conduct our studies, we 
utilize high pressure focused ultrasound in combination with injected microbubbles to cause 
hemorrhage. We applied this technique at two different pressures resulting in striatal hemorrhage 
induction with distinct phenotypic outcomes. Following induction at the higher-pressure, mice 
show evidence of lateral motor deficit and other signs of impairment. Mice with hemorrhage 
induced at the lower pressure show no behavioral signs of neurological deficit. We employ 
immunofluorescence and western blotting to understand the cellular responses to intracerebral 
hemorrhage in these mice. We find evidence of inflammation and cell death following high-
pressure induction of intracerebral hemorrhage. Lower pressure induction of intracerebral 
hemorrhage lacks signs of cell death but shows apparent inflammation. We have created a novel 
 
 
pressure-dependent mouse model of symptomatic and asymptomatic intracerebral hemorrhage 
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Chapter 1: Introduction 
1.1 Neurologic disease: stroke 
Stroke, the broad term referring to compromised blood flow within a region of the brain 
resulting in acute focal neurologic impairment, is also referred to as a cerebrovascular 
accident[1]. Originally identified symptomatically, imaging such as Computed Tomography 
(CT) and Magnetic Resonance Imaging (MRI) have allowed further identification of what is 
broadly considered stroke into categories based on mechanism of brain injury[1-4]. These 
categories include ischemic and hemorrhagic stroke. Hemorrhagic stroke is further 
subcategorized into subarachnoid hemorrhage and intracerebral hemorrhage based on the site of 
origin of the hemorrhage[2].  
The predominant subtype of stroke is ischemic, accounting for approximately 80% of 
stroke incidence[1]. Ischemic stroke is a condition in which an artery within the brain is occluded 
either by thrombus or embolism resulting in a lack of perfusion to the brain region supplied by 
the affected artery[1]. If the blockage of the blood vessel is transient, the result may be a 
transient ischemic attack defined as a focal neurologic deficit lasting up to 24 hours[1]. More 
long-lasting blockages can cause ischemic stroke. The presentation depends on the blood vessel 
that is blocked, and which brain region is impaired. Outcomes can include hemiparesis and 
hemiparalysis, hemineglect, speech difficulty, blindness, and loss of coordination for blockages 
affecting the cerebral cortex, and cerebellum respectively[5].  
Risk factors for stroke include advanced age, hypertension, diabetes, and smoking[1, 6-
8]. Ischemic stroke is a neurologic emergency requiring rapid identification and treatment[9]. 
Prolonged duration of cerebral hypoperfusion is associated with increased cellular death and 
neurologic dysfunction[1]. Potential treatment modalities include pharmacologic and mechanical 
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interventions. Tissue plasminogen antigen (TPA) has been long appreciated for the ability to 
reverse the effects of ischemic stroke if administered within the treatment window [9]. 
Endovascular interventions to remove clots involved in ischemic stroke have gained 
popularity[10].  
Hemorrhagic transformation represents a critical complication of ischemic stroke 
previously seen in up to 43% of ischemic stroke patients[11, 12]. Hemorrhagic transformation is 
associated with worsened outcomes therefore a fine balance must be achieved between the 
prevention of excessive coagulation and the prevention of hemorrhage[9, 13, 14]. This 
complication limits options for ischemic stroke treatment and prevention of recurrence as 
interventions to eliminate clots and reduce coagulation have substantial potential to promote 
hemorrhage[9, 11, 15-18]. Due to the relationship between treatment of ischemic stroke and 
induction of hemorrhage, an improved understanding of intracerebral hemorrhage poses potential 
beneficial for treatment and secondary prevention of ischemic stroke.   
1.1.1 Intracerebral hemorrhage 
Intracerebral hemorrhage includes hemorrhagic stroke, subarachnoid hemorrhage and 
cerebral microbleed[2]. Although less prevalent than ischemic stroke, hemorrhagic stroke 
accounts for a large portion of stroke mortality and morbidity and has been determined to be a 
major contribution to neurologic disease burden globally[19, 20]. For these reasons the 















Contribution of specific causes to the combined burden of neurologic disorders and cerebrovascular disease 
(percent of total disability-adjusted life-years) 
Source: GBD 2010 Results by Cause 1990–2010.  
 
Global burden of neurologic disease by disability adjusted life-years shows 35.7% of the burden 
of neurologic is caused by hemorrhagic stroke. Adapted from [19] 
 
Although hemorrhagic stroke has been a subject of intense study for decades, there exist 
few treatment options for patients suffering from this stroke subtype[21-23]. The 
pathophysiology of hemorrhagic stroke remains incompletely understood however clues from 
risk factors have informed current beliefs about the origin of spontaneous intracerebral 
hemorrhages[2, 24]. 
The pathophysiology of primary spontaneous hemorrhagic stroke is believed to begin 
with prolonged elevated intravascular pressure within the intracerebral arteries[25]. Under the 
constant pressure, the walls of the blood vessels weaken and subsequently rupture sending blood 
products into the brain parenchyma[25]. This leads to the formation of a hematoma that may 
compress brain structures resulting in a mass effect, known as the primary injury. The hematoma 
and surrounding edema also may compress the surrounding vasculature causing a region of 
ischemia[24]. The breach of the blood brain barrier triggers inflammation and cell death within 
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the region affected by the hemorrhage contributing to pathology known as the secondary 
injury[26].  


















               Schematic representation of the pathophysiology of intracerebral hemorrhage.  
                Adapted from [25] 
 
Hemorrhagic stroke is classified as primary or secondary depending on an origin that is 
spontaneous or due to a pre-existing condition respectively[1, 24]. The majority of hemorrhagic 
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stroke cases are of the primary subtype occurring within the deep structures of the brain such as 
the striatum[27]. Predisposing factors for primary hemorrhagic stroke include age, hypertension, 
and geographic location[8, 20]. The rising use of anticoagulation is also believed to contribute to 
the prevalence of intracerebral hemorrhage[14].  
Sex differences have been noted in intracerebral hemorrhage incidence with females 
showing a lower incidence than males within most stratified age groups[28]. Estrogen has been 
noted to reduce edema resulting from iron exposure and poses a potential mechanism for 
neuroprotection in females[29]. 
Outcomes following intracerebral hemorrhage are predicted by factors including the 
initial hemorrhage volume, hematoma location, hematoma expansion, the Glasgow Coma Score, 
the presence of intraventricular hemorrhage and age of the patient[1, 2, 12, 22]. Clinical 
evaluation of intracerebral hemorrhage includes imaging with Computed Tomography (CT) or 
Magnet Resonance Imaging (MRI)[3, 22]. On contrast enhanced CT there may be a focal region 
of hyperdensity corresponding to contrast extravasation. This finding, referred to as the spot sign, 
is associated with hematoma expansion[12]. Hematoma expansion, defined as an increase of 
hematoma volume by 33% from initial imaging, is associated with increased mortality and 
morbidity following hemorrhagic stroke[30]. On MRI, the appearance of intracerebral 
hemorrhage varies over time due to changes in the magnetic properties of the hematoma[31]. 
1.1.2 Hemorrhagic stroke therapies and clinical studies 
Hemorrhagic stroke is a clinical emergency requiring immediate evaluation and 
intervention[24]. The mass effect following hemorrhagic stroke has the potential to cause 
herniation of brain structures resulting in severe neurologic dysfunction and death[22, 32, 33]. 
Clinical management of intracerebral hemorrhage involves initial diagnosis via clinical suspicion 
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confirmed by imaging with either MRI or CT[2, 21, 22]. Current therapies for hemorrhagic 
stroke are largely supportive including blood pressure correction and monitoring of intracranial 
pressure[21-23, 34].  
The approach to treatment of intracerebral hemorrhage is informed by numerous clinical 
studies on the subject[33, 35, 36]. Over 280 clinical trials have been reported involving 
intracerebral hemorrhage with the goal of developing a better understanding of disease 
progression and testing potential therapeutic interventions. Key trials that influence modern 
understanding and treatment of intracerebral hemorrhage include the Antihypertensive Treatment 
of Acute Cerebral Hemorrhage (ATACH) trial and the Surgical Treatment of Intracerebral 
Hemorrhage (STICH) trial[35, 37].  
Since the initial finding of the ATACH trial that early blood pressure control is beneficial 
to patients, there have been various additional trials and subgroup analyses seeking to address the 
optimal timing, populations, and goals of blood pressure control in ICH patients[35, 36, 38-40]. 
The ATACH II trial compared an intensive blood pressure goal (systolic blood pressure of 110-
139) to standard control (systolic blood pressure of 140-179) finding no difference in mortality 
or disability between the two groups[36]. Subgroup analysis of the ATACH-2 trial demonstrates 
a reduction of hematoma expansion and overall hematoma size following spontaneous basal 
ganglia ICH however the functional outcomes were not altered[27]. There is interest in utilizing 
the spot sign to stratify patients likely to benefit from treatments such as intensive blood pressure 
control[41].  
Surgical removal of the hematoma was shown to have little benefit when applied broadly 
to ICH populations in the STICH trial[37]. Surgical treatment in intracerebral hemorrhage 
remains an active area of study with the goal of identifying patients likely to benefit[42-45].   
7 
 
Various neuroprotective agents have been targeted following promising results in 
preclinical studies including minocycline and deferoxamine[46-48]. However further studies are 
needed to determine potential efficacy in humans. Deferoxamine, an iron chelator has been 
shown to be beneficial in animal studies of intracerebral hemorrhage[49]. Clinical trials however 
have not seen the same success thus far. The Deferoxamine mesylate in patients with 
intracerebral hemorrhage (i-DEF) trial found safety in administration of deferoxamine in ICH 
patients but did not find sufficient efficacy to warrant a phase III trial[47]. The disconnect 
between the development of promising treatment options in preclinical research often conducted 
with rodent studies and the lack of efficacy in human trials details a need to better understand the 
key contributors of the disease to pathology as well as to understand how the models compare to 
human disease. There exists the need for additional animal models of intracerebral hemorrhage 
to facilitate understanding of critical elements of intracerebral hemorrhage pathophysiology 
1.1.3: Cerebral microbleed 
A cerebral microbleed is defined as one or more circular or elliptical areas of hemorrhage 
of 2-10mm in diameter on MRI imaging[50]. The increased use of cerebral imaging in addition 
to the application of more sensitive MRI sequences to imaging protocols have led to an increased 
appreciation for the prevalence of cerebral microhemorrhage[50]. Cerebral microbleeds are 
associated with vascular disease including hypertension and cerebral amyloid angiography[3, 50, 
51]. They are also considered to be a predisposing factor for the development of intracerebral 
hemorrhage, ischemic stroke, and dementia. Inflammation has been found in cerebral 
microhemorrhage[52]. Although cerebral microhemorrhage is often asymptomatic, the 
prevalence of cerebral microbleeds in the setting of neurologic disease demonstrates the 
importance of understanding the associated pathology.  
8 
 











                               Axial MRI with numerous cerebral microhemorrhages. 
                                  Adapted from [53] 
 
1.1.4 Mouse models of intracerebral hemorrhage 
Animal models have been critical to our understanding of the pathophysiology of various 
diseases[54]. Categories of animal models of focal neurologic disease include inducible and 
spontaneous. In inducible models, pathology is directly caused by an intervention. Spontaneous 
models of disease often rely on replicating risk factors of the disease of interest predisposing 
mice to develop pathology.  
Multiple rodent models of intracerebral hemorrhage have been created to probe the 
cellular and molecular pathways involved in intracerebral hemorrhage pathology[55]. The 
striatal balloon inflation technique initially described by Sinar et. al. involves the injection of a 
syringe surrounded by a balloon with subsequent inflation[56]. This model recreates the primary 
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effect of the pressure of the hematoma on the parenchymal structures resulting in cerebral blood 
vessel compression and ischemia however there is no blood toxicity or secondary injury of 
intracerebral hemorrhage[56]. This model is used less frequently as other models of hemorrhagic 
stroke have become increasingly favored.  
Autologous blood injection was described by Ropper et al.[57]. This model is generated 
by obtaining blood and injecting it into the target region. The autologous blood injection model 
causes a mass effect and reproduces the effects of blood toxicity on the brain. The autologous 
blood injection model does not involve vascular damage[55, 57].  
The collagenase injection model of hemorrhagic stroke described by Rosenberg et. al. is 
achieved by injecting bacterial collagenase into the target region[58]. The collagenase degrades 
the extracellular matrix leading to blood vessel rupture. This model induces the mass effect, toxic 
effects of blood and vascular rupture but does not involve increased intravascular pressure[55].  
Spontaneous models of intracerebral hemorrhage exist that generate long standing 
hypertension in the mice and result in spontaneous intracerebral hemorrhage. Renal artery 
ligation in addition to a high salt diet are techniques employed to induce chronic hypertension in 
mice[55]. This technique is likely to closely replicate the pathophysiology of human 
intracerebral hemorrhage as the predisposing factor of prolonged elevated blood pressure is 
involved in both. The spontaneous nature of the development of intracerebral hemorrhage poses 
challenges for studying the development of pathology within these models. As the hemorrhage 
occurs spontaneously, it is difficult to know the time of hemorrhage onset.  
There are both spontaneous and inducible models of cerebral microbleed[59]. Non-
spontaneous induction of cerebral microhemorrhage involves laser-induced vessel ablation under 
the guidance of two photon imaging for vessel localization[60]. This model induces a single 
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microhemorrhage targeted to a vessel of interest[60]. The laser-induced cerebral microbleed 
model requires creation of a cranial window for two photon imaging of the target vessel. Due to 
the requirement of two photon imaging for identifying a target vessel, this technique is only 
applicable to cortical regions[59]. Spontaneous cerebral microbleeds are created via genetic 
overexpression of APP creating a model of CAA. Hypertensive mice are also used as a model of 
spontaneous intracerebral hemorrhage[59].  
Although various mouse models of intracerebral hemorrhage exist, there remains a need 
for the development of additional models to further facilitate intracerebral hemorrhage research. 
The American Heart Association highlights areas of particular interest for novel models of 
intracerebral hemorrhage including inducible models, hemorrhage enlargement and resolution, 
with the ability to target different regions of the brain[61]. 
1.2 Neuroinflammation: Microglia and Astrocytes 
Microglia are the resident immune cells of the central nervous system. Derived from cells 
in the myeloid lineage, microglia represent a unique cell type within the brain[62]. During 
homeostasis microglia exhibit a ramified morphology with a small cell body and numerous long 
processes with many branches[63]. This morphology facilitates constant surveillance of the 
surrounding environment[64].  
Activation of microglia has been an active area of investigation. Morphological changes 
have been observed in microglia confronting a neurological insult[63]. Microglia in pathologic 
states have been found to have a more amoeboid morphology with fewer branches[63]. 
Additional assays of microglia have provided more detailed understanding of microglial 
reactions to neurologic pathology. CD68 is a lysosomal associated protein found in microglia 
thought to be associated with phagocytic activity within the microglia[65]. CD68 is found to 
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increase in microglia responding to disease states[65, 66]. RNA sequencing has allowed for 
further characterization of microglia in multiple states including the recognition of disease 
associated microglia (DAM)[67-71].  









      Representation of progressively activated Microglial states. Adapted from [72] 
 
Early descriptions of the activation state of microglia described two distinct forms: M1 
and M2 that promote increased inflammation or repair respectively[73, 74]. The accuracy of this 
microglial polarization paradigm has come into question. RNA sequencing and other methods of 
study have provided a more detailed understanding of the various microglial populations in 
existence replacing the M1 vs M2 classification scheme[68-70, 75]. 
Cultured microglia have been utilized to gain an understanding of the functions of this 
cell type in a more controlled environment. In culture microglia have been shown to require 
caspase 8 activity for activation[76]. Downstream caspases including caspase 7 and caspase 3 are 
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also required[76]. The response of microglia to hemorrhage has also been addressed. Animal 
models have demonstrated microglial response to intracerebral hemorrhage[77].  
Microglia rely on constant colony stimulating factor CSF1 and CSF1R interaction for 
survival[78, 79]. Therefore, inhibition of CSF1R with compounds such as plx3397 create near 
complete depletion following treatment[80, 81]. Models of intracerebral hemorrhage in which 
microglia have been depleted prior to induction of intracerebral hemorrhage demonstrate a 
reduction in the size of the hematoma[80]. This finding suggests that the role of microglia in the 
pathophysiology of intracerebral hemorrhage goes beyond hematoma clearance and is capable of 
contributing to the development of larger rather than smaller hematomas. The suggestion of an 
adverse impact of microglia has led to an interest in reducing the effect of microglia on 
intracerebral hemorrhage with the goal of reducing the size of the hematoma and improving 
outcomes[82]. Animal models have demonstrated benefit in potential therapeutic options that 
show reduced microglial activation including minocycline and pioglitazone[83, 84].  
Astrocytes are an abundant cell type within the brain now recognized for having various 
essential roles within the central nervous system[85]. Astrocyte end feet form a critical 
component of the blood-brain barrier[86]. Astrocytes have been found to be involved in various 
disease processes including stroke, multiple sclerosis, and Alzheimer’s Disease[82, 85, 87, 88]. 
Similar to microglia, there have been studies assessing the differences between astrocytes in the 
healthy brain and astrocytes in disease states[85]. Astrocytes are noted to undergo morphological 
changes in the setting of pathology appreciable by labeling with the astrocyte marker GFAP[89]. 
In physiologic conditions, astrocytes show a highly branched, stellate, morphology[90]. Disease 
states have shown shift toward hypertrophic astrocytes and upregulation of GFAP[90]. 
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1.3 Cell death pathways  
The regulation of cell death is a critical function to maintain the integrity of an 
organism[91]. While excessive cell death is a contributing factor to diseases such as 
neurodegeneration, inadequate cell death can facilitate uncontrolled cellular proliferation, a 
feature of cancer pathogenesis[91, 92]. Therefore the appropriate balance must be achieved in 
order to ensure the health of the organism.  
Long studied forms of cell death include necrosis and apoptosis[91, 93]. Lately cell death 
pathways with differing components and hallmarks have been identified including pyroptosis, 
necroptosis, and ferroptosis[92, 94-99].  
Apoptosis 
Apoptosis is a highly regulated form of cell death. Cell death via apoptosis results in little 
impact on the surrounding environment of the cell[91]. Cells enter apoptosis through one of two 
major pathways termed the intrinsic and the extrinsic pathway[91]. Cytotoxic signals trigger a 
cascade of protein changes within the mitochondria. Critical components include cytochrome C, 
apoptotic protease activating factor 1(APAF1), inhibitors of apoptosis (IAPs), and caspases 9, 3, 
6, and 7[91]. The extrinsic pathway of apoptosis is ligand dependent and is thus known as the 
death receptor pathway. Fas ligand binds to FAS. Induction of caspase 8 dimerization and 
autocleavage leads to downstream activation of executioner caspases and cell death[91]. 
Morphologic characteristics of cells that have undergone apoptosis include DNA fragmentation, 







The uncontrolled pathway of cell death is termed necrosis. This cell death form notably 
causes regional damage and inflammation due to exposure of the surrounding area to the 
contents of the dying cell[91]. Causes of necrosis include hypoxia and inflammation[91]. 
Necroptosis 
In 2005, a form of cell death exhibiting features of necrosis through a regulated induction 
pathway was described[100]. Necroptosis shows features similar to the extrinsic pathway of 
apoptosis considering the involvement of receptor-mediated cell death[98]. Necroptosis involves 
the phosphorylation of Mixed Linkage Kinase domain Like pseudokinase (pMLKL) with 
subsequent oligomerization and translocation to the cell membrane inducing pore formation, cell 
permeabilization, and cell death with the release of intracellular contents into the surrounding 
area[98]. This process is inhibited by necrostatin-1[101]. Necroptosis has been shown to be 
involved in cell death in response to blood toxicity suggesting a role in intracerebral 
hemorrhage[101].  
Pyroptosis  
Pyroptosis is a form of inflammatory cell death involving cleavage of caspase 1 with 
downstream activation of IL-1 beta[94]. Features of pyroptosis include a combination of cell 
death with release of inflammatory cytokines[94, 96]. This form of programmed cell death has 
been suggested to play a role in the pathophysiology of neurologic disease including Alzheimer’s 
Disease and stroke[88, 102, 103]. As various neurologic conditions involve a robust 






Ferroptosis was initially described in 2012 as an iron dependent non-apoptotic form of 
cell death[95]. This cell death pathway has been an active area of study for cancer and 
neurologic disease[104-109]. Early studies of this cell death pathway evolved from the discovery 
that erastin was capable of inducing a unique form of cell death that is modulated by intracellular 
iron levels and involves increases in reactive oxygen species (ROS)[95, 110]. The ferroptotic 
pathway involves activity of the iron-dependent enzyme lipoxygenase which promotes 
downstream lipid peroxidation and cell death[111-114]. Ferroptosis is inhibited by the iron 
chelator deferoxamine as well as by antioxidant treatment and ferrostatin 1[95]. As intracerebral 
hemorrhage involves the presence of both elevated iron and reactive oxygen species, the role of 
ferroptosis following cerebral hemorrhage is an active area of investigation[101, 104, 106].  
1.4 Focused Ultrasound 
In 1880 Jacques and Pierre Curie published an essential observation; in certain crystals, 
physical energy such as mechanical compression is converted into an electrical current[115]. The 
phenomenon they described is now known as the piezoelectric effect which forms the basis of 
ultrasound technology[116]. The possibility of altering the shape of the crystal to generate 
differential properties of ultrasound was demonstrated in 1935 by shaving the quartz crystal into 
a convex shape resulting in a focusing of the ultrasound waves to a target point[116].  
Numerous parameters describe the character of both planar (unfocused) and focused 
ultrasound. Changing any of these parameters will result in ultrasound that exhibits distinct 
features[117].   
Amplitude describes the pressure differential of the ultrasound. The difference between 
the peak pressure (or minimum pressure) and the average pressure is the amplitude[117]. 
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Ultrasound is a mechanical pressure that has two phases a compressive phase applying a positive 
pressure on the target of ultrasound and a rarefactional phase imposing a negative pressure. 
Amplitude, described in units of decibels, is modifiable and can be manipulated by the operator 
to generate differential effects of ultrasound.  
Ultrasound power, reported in Watts, is calculated as the square of the amplitude[117]. 
The power per unit area of the targeted region is termed the intensity of ultrasound and is 
reported as Watts/cm2.This is the primary parameter utilized to describe the safety of ultrasound 
and predict resultant biological effects[117].  
The biological effects of focused ultrasound were reported in the 1920s[118]. These 
reports described the effect of ultrasound on cells indicating the potential for ultrasound to be 
applied to and alter animal cells and tissues. In addition to mechanical effects induced by focused 
ultrasound, the biological changes in tissues subjected to focused ultrasound are dependent on 
factors such as thermal and neuromodulatory effects[119-124].  
Thermal: Focused ultrasound has been found to induce heating in the target tissue[119, 
121-123]. The heating is a result of ultrasound absorption by tissues with the conversion from 
mechanical energy to thermal[117]. The temperatures achieved with focused ultrasound can be 
of a sufficient level to cause tissue ablation. This is a component of the mechanism of focused-
ultrasound tumor ablation[122].  
Neuromodulation: Low frequency focused ultrasound has been found to cause 
alterations in neuronal activity[124, 125]. Both increases and decreases in neuronal firing have 
been observed following focused ultrasound. This technique has therapeutic potential to diseases 
involving of aberrant neuronal firing such as epilepsy[126].  
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1.4.1 Applications: Therapeutic 
Focused ultrasound has been extensively studied for transient opening of the blood-brain 
barrier[127-132]. An essential regulator for maintaining the integrity of the brain, the blood-brain 
barrier restricts the transit of circulating components into the brain parenchyma[86]. This barrier 
poses a challenge for therapeutics that are targeted to the brain parenchyma restricting access 
from the vasculature to the brain. The safe and reversible opening of the blood brain barrier with 
focused ultrasound has been reproducibly achieved[128, 130]. Ultrasound generates a physical 
disturbance of materials. Classically gas particles within liquids are particularly susceptible to 
alteration under the pressure of the ultrasound beam in a process called cavitation[133]. 
Cavitation is defined as stable involving oscillation of the gas bubbles, or inertial involving 
collapse of gas bubbles sending shockwaves into surrounding material[134]. Injection of 
circulating microbubbles facilitates cavitation by introducing additional gaseous inclusions to the 
system[135, 136]. The safe reversible opening of the blood-brain barrier involves predominantly 
stable cavitation with limitations to parameters including peak rarefactional pressure, ultrasound 
intensity, and microbubble dose[129, 135, 137]. 
Focused ultrasound has been found to lead to an activation of microglia with parameters 
capable of inducing blood-brain barrier opening[129, 138, 139]. This observation led to the 
application of focused ultrasound for microglial priming[140, 141]. This is the idea that 
microglia can be prepared for a biological insult if they are first activated via the application of 
focused ultrasound. This is an area of investigation for diseases including Alzheimer’s disease in 
which microglial priming may result in enhanced plaque clearance[140].  
An exciting potential application for focused ultrasound is clot thrombolysis[142]. This 
application is quite intriguing for ischemic stroke which involves the blockage of an artery in the 
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brain leading to hypoperfusion and impaired function of the affected brain region[1]. Mechanical 
thrombolysis via endovascular surgery is an accepted treatment for ischemic stroke[10]. Focused 
ultrasound has been studied for stroke treatment both alone and in combination with 
pharmaceutical thrombolysis[143-145]. Further investigation with increasingly physiologic 
conditions will be required to determine and optimize the benefit of focused ultrasound 
application to clot lysis.  
1.4.2 Applications: Disease Models 
The ability to use focused ultrasound to model and study disease states dates back as far 
as the 1940s[146]. At Columbia University, studies by Lynn and Putnam demonstrated 
behavioral deficits correlating to the region exposed to focused ultrasound. They observed 
temporary blindness following focused ultrasound to the occipital lobe, ataxia following 
cerebellar focused ultrasound, and paralysis and loss of sensation following spinal cord damage 
via the use of focused ultrasound. At the time of the study, it was realized that this could aid in 
the understanding of human neurologic disease. Later studies of high intensity focused 
ultrasound replicated additional pathologies including neuronal destruction and lung 
hemorrhage[147, 148]. Animal models of disease are a key contributor to our understanding of 
the human condition. Focused ultrasound has been successfully applied to generate damage 
similar to that seen in human disease thus providing a promising system for the creation of 






Chapter 2: Materials and Methods 
2.1 Mouse husbandry 
All experiments were conducted in accordance with IACUC and AAALAC regulations.  
C57BL/6J mice (stock number 000664) were ordered from Jackson Laboratories and 
housed in a barrier facility for at least 72 hours prior to experiments. Mice are provided with a 
standard diet and water ad libitum with biweekly cage changes. Mice are on a 12-hour light-dark 
cycle with light from 6am-6pm. Experiments were conducted on mice age 16-20 weeks of age.  
Female mice were housed together for two weeks to synchronize estrus cycles. 
2.1.1 Intracardiac perfusion 
Mice are given a mixture of Ketamine and Xylazine 75-95 mg/kg and 5-7 mg/kg 
respectively diluted in normal saline via intraperitoneal injection. Following injection mice are 
assessed every 5 minutes for respiration and extinction of the toe pinch reflex. Once the level of 
anesthesia is adequate shown by extinction of the toe pinch reflex and slowed breathing fur is 
removed from the chest. The transthoracic cavity is exposed, and the right atrium is clipped. A 
needle is inserted into the left ventricle and ice-cold saline is pumped into the circulation at a rate 
of 6 ml/minute. A total of 12 ml of saline are infused. For immunohistochemical analysis 12 ml 
of 4% paraformaldehyde are infused following the saline infusion.  
2.2 Focused ultrasound Application 
Prior to use lab-manufactured microbubbles are activated with 20 second alternating 
cycles of vacuum and decafluorobutane then mixed thoroughly for even microbubble 
distribution. Degassed water is inserted into the head of a 1.5 MHz ultrasound transducer 
ensuring that no bubbles are present. The transducer is covered with a latex membrane.  
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Anesthesia is induced with isoflurane at 2.75% in an induction chamber. Mice are 
transferred to a warming pad and placed within the stereotactic apparatus with 1.5 to 2.75% 
isoflurane continuously supplied via nose cone. Cranial fur is removed first with clippers then 
with depilatory cream. Lubricating ointment is applied to both eyes. Ultrasound gel is applied to 
the scalp and a chamber of degassed water is placed upon the scalp and gel with a grid placed 
within the degassed water chamber directly above the lambda suture.  
Targeting: Ultrasound is used to image the metal grid and position the focus of the 
ultrasound directly above the lambda suture. Once targeting is complete the transducer is moved 
5.5 mm anterior and 1.5 mm to the right of the lambda suture.  
FUS-ICH 2.5: For Focused Ultrasound-Induced Intracerebral Hemorrhage at 2.5 MPa 
(FUS-ICH 2.5), microbubbles are introduced via tail vein immediately preceding application of 
focused ultrasound. Focused ultrasound is applied with a 1.5 MHz transducer, pulse length (PL) 
of 10,000 cycles, pulse repetition frequency (PRF) of 5 and a peak rarefactional pressure is 2500 
kPa, total duration 60 seconds[149, 150]. Cavitation results are recorded during the focused 
ultrasound application. Once the procedure is complete, mice are placed on a warming pad as 
they recover from anesthesia with continuous monitoring until full recovery is achieved.  
FUS-ICH 1.5: For FUS-ICH at 1.5 MPa (FUS-ICH 1.5), mice are subjected to the 
procedure as described for FUS-ICH 2.5 with a peak rarefactional pressure of 1500kPa rather 
than 2500kPa[149, 150].  
FUSO: For Focused Ultrasound Only (FUSO), mice are prepared as described FUS-ICH 
2.5 but no microbubbles are injected prior to the application of focused ultrasound[150]. 
Sham: Mice are placed in the anesthesia induction chamber with 2.75% isoflurane. Once 
sufficient induction of anesthesia is achieved, mice are transferred to a warming pad within a 
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stereotactic apparatus with continuous 1.5 to 2.75% isoflurane supplied via nose cone. Cranial 
fur is removed with clippers and depilatory cream. Mice are allowed to recover from anesthesia 
on a warming pad with continuous monitoring until full recovery is achieved[149, 150].  
2.3 MRI 
Induction of anesthesia is achieved with 2.5% isoflurane. Once anesthetized, mice are 
placed into a chamber and inserted vertically into the Bruker 9.7T Magnet. Anesthesia is 
maintained at 2% continuously administered via nose cone. Images are obtained using Paravision 
software.  
T2 weighted MRI (T2W MRI): Images were acquired using the following parameters: 
echo time (TE) 30 ms, repetition time (TR) 2500 ms, 6 averages, 1 repetition, echo spacing 10 
ms, rare factor 8, slice thickness 0.4 mm. T2 images were acquired prior to injection with 
gadolinium. 
Gadolinium enhancement: 200 microliters of gadolinium (Omniscan) is injected into 
the intraperitoneal cavity of mice at least 20 minutes prior to imaging.  
T1 Weighted MRI (T1W MRI): Gadolinium enhanced T1 weighted images were 
acquired using the following settings: TE 3ms, TR 230ms, 6 averages, 70 degree flip angle, slice 
thickness 0.4 mm.  
2.4 Behavioral assays 
Neuroscore: Mice are provided a score correlating to physical condition based upon 
whether they are circling, their level of motility, and general appearance. A high neuroscore 
correlates to a normal mouse and a low neuroscore represents a mouse with severe neurologic 
impairment. Circling is scored with a maximum of 4 points for no circling behavior, 3 points for 
spontaneous large diameter circling, 2 points for spontaneous small diameter circling, 1 point for 
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circling when pulled by tail, and 0 points for no movement. Motility is scored with a maximum 
of 3 points for a normally and actively moving mouse, 2 points for a mouse that is actively 
moving but with an unsteady gait, 1 point for a mouse that is reluctant to move, and 0 points for 
a mouse with no spontaneous movement. General appearance has a maximum score of 3 points 
for a normal well-groomed mouse, 2 points for a well-appearing mouse with at least 5% weight 
loss, 1 point for a well-groomed mouse with hunched posture, 0 points for a mouse with hunched 
posture and evidence of decreased grooming.  
Corner Turn Test: Motor function of mice is assessed using the corner turn test. Mice 
are placed into a plexiglass corner with glass panes angled to 30 degrees with a .5 cm space 
between the two panes. Once the mouse is inserted into the corner it is observed for a turn 
completion. Only turns in which the mouse rears fully onto one side of the apparatus before 
turning are counted. The test is run for 10 trials. The corner turn test apparatus is cleaned 
thoroughly with ethanol between mice.  
2.5 Histochemistry 
2.5.1 Immunofluorescence 
20-micron sections: Brains following perfusion are post fixed in 4% paraformaldehyde 
overnight at 4 degrees Celsius. Tissues are washed 3 times with 1X Phosphate Buffer Solution 
(1X PBS) then incubated in 30% sucrose for at least 24 hours prior to embedding in OCT on dry 
ice. Sections 20 microns in depth are achieved with a cryostat.  
 Slides are washed with PBS 3 times, permeabilized in blocking buffer with 0.1% triton 
for 30 minutes, then incubated in blocking buffer (10% NGS, 1% BSA, in PBS) for 1.5 hours at 
room temperature. After blocking, slides are incubated in primary antibody diluted in blocking 
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buffer over night at 4 degrees Celsius. Antibody concentrations and details are provided in 
antibody table.  
Slides are washed 3 times with 1X PBS then incubated in secondary antibody and 
directly labeled primary antibodies for 2 hours at room temperature followed by 3 washes with 
1X PBS. Hoechst stain is applied for 5 minutes (dilution, 1:1000) then slides washed 3 times 
with 1X PBS Mounted onto a microscope slide with mounting media and coverslip is applied. 
150-micron sections: Brains following perfusion are post fixed in 4% paraformaldehyde 
overnight at 4 degrees Celsius. Tissues are washed 3 times with Phosphate Buffer Solution and 
stored in Phosphate Buffer solution prior to sectioning. Sections 150 microns in depth are 
achieved using a vibratome. Slices are stored in Phosphate Buffer Solution with 0.1% sodium 
azide until use.  
 Sections are stained free floating. Tissues are washed with 1X PBS 3 times and 
permeabilized in blocking buffer with 1% Triton for 1 hour at room temperature then incubated 
in blocking buffer for 2 hours at room temperature. Tissues are incubated in primary antibody 
diluted in blocking buffer over 48 hours. Tissues are washed 5 times for 10 minutes each then 
incubated in secondary antibody and directly labeled primary antibodies overnight. Brains are 
washed 5 times for 10 minutes each. A Hoechst stain is applied for 15 minutes (dilution, 1:1000). 
Sections are mounted onto a microscope slide with mounting media and coverslip is applied.  
TUNEL: Terminal dUTP nick end labeling is achieved using the assay kit from 
Promega. Slides with 20-micron thick brain slices are washed with PBS followed by 10 minute 
incubation in proteinase K at room temperature. Following an additional wash with PBS, slides 
are incubated in equilibration buffer for 10 minutes at room temperature then incubated in 
reaction mixture consisting of fluorescently labeled nucleotides and the rTDT enzyme for 1 hour 
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at 37 degrees. The reaction is stopped with 2X SCC for 15 minutes at room temperature then 
washed with PBS. Immunofluorescence co-staining follows with the typical protocol described 
above.  
To generate a positive control, the proteinase K permeabilization step is followed by 
incubation with DNase buffer (40mM Tris-HCL, 10mM NaCl, 6mM MgCl2, 10mM CaCl2 in 
deionized water) for 5 minutes and incubation with DNase (10 units) in DNase buffer.  
A negative control is achieved by following the TUNEL procedure with the exclusion of 
the rTDT enzyme from the reaction mixture.    
            2.5.2 Hematoxylin and Eosin 
Slides with 20-micron sections are used. Hematoxylin and Eosin (H&E) staining is 
performed by the Columbia University histology core.  
2.6 Biochemistry 
2.6.1 Western Blot 
Following perfusion with ice cold saline brains are collected and dissected. The right 
hemisphere from 2mm-6mm anterior to lambda is collected and further dissected into medial and 
lateral halves. The medial portion is used for experiments. Dissected brain tissue is flash frozen 
in liquid nitrogen then transferred to -20 degree Celsius until lysis. Tissues lysed with Abcam 
cell lysis buffer with added phosphatase and protease inhibitors. Tissues are homogenized with a  
mechanical homogenizer. Lysates are sonicated then centrifuged at 12,000 rpm for 20 minutes at 
4 degrees Celsius. The supernatant is collected into a fresh tube.  
Protein from brain lysates is quantified via BCA assay and 30 micrograms of protein are 
prepared with Laemmli buffer with 20% beta mercaptoethanol (BME). BME is excluded from 
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the preparation of samples to be probed with CD68. The protein solutions are then heated at 100 
degrees Celcius for 5 minutes and allowed to cool to room temperature prior to loading.   
Samples are run on Novex 10-20% tris-glycine gels at 160 mV for 30 minutes followed 
by 120 mV for one hour.  
Proteins are transferred to a PVDF membrane following membrane activation with 100% 
methanol for 30 seconds and equilibration in transfer buffer. Transfer is conducted at 0.3 amps 
for 2 hours. 
Membranes are incubated in Revert total protein stain solution for 5 minutes followed by 
30 seconds in Revert wash solution. Total protein staining is imaged with the Licor Odyssey 
system using image studio software. Membranes are then incubated in Licor blocking buffer for 
1 hour at room temperature then incubated in primary antibody diluted in Licor blocking buffer 
overnight. Antibody dilutions are listed in the antibody table. Membranes are then washed 3 
times with 1x Tris-Buffered Saline (TBS) with 0.1% Triton then incubated in Licor secondary 
antibody (1:10,000 dilution). Washes with 1x TBS with 0.1% Triton are removed, the 











Table 2.1: Antibody Catalogue  
Antibody Company Catalog 
Number 
































































































Chapter 3: FUS-ICH at 2.5 MPa Hemorrhage and Behavior 
3.1: Introduction 
The understanding of human intracerebral hemorrhage relies on the study of animal 
models. Intracerebral hemorrhage is modeled in a number of ways including direct injection of 
autologous blood from a mouse’s tail artery or injection of bacterial collagenase into the target 
region of the brain[55]. The autologous blood injection model reproduces the effects of blood 
toxicity within the brain as well as the mass effect[55]. The collagenase injection method induces 
vessel rupture through the destruction of the extracellular matrix and induces blood toxicity and 
the mass effect. There remains a need for additional models of intracerebral hemorrhage 
according to the American heart association round table discussion[61]. As hypertension is an 
essential risk factor for the development of intracerebral hemorrhage, the involvement of 
mechanical intravascular pressure in an inducible model is of interest[1]. Of specific interest 
within models of intracerebral hemorrhage is the induction of a dynamic hematoma that expands 
and resolves over time as both hematoma expansion and resolution have been observed in human 
intracerebral hemorrhages and are believed to contribute to human intracerebral hemorrhage 
pathophysiology[61].  
Focused ultrasound is a technique capable of inducing transient BBB opening[128, 130]. 
This ability has led to numerous studies probing therapeutic benefits of FUS[127, 128, 131, 132, 
142, 143]. However, FUS has been noted to cause vessel rupture at pressures above the 
therapeutic threshold[130]. This finding raises the possibility of utilization of focused ultrasound 
technology for induction of vascular damage incited by a mechanical pressure-dependent insult.  
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To our knowledge the Focused Ultrasound induced Intracerebral Hemorrhage (FUS-ICH) 
model is the first inducible pressure-dependent mouse model of intracerebral hemorrhage[149, 
150].  
3.2: FUS-ICH Procedure 
The setup for the Focused ultrasound induced intracerebral hemorrhage mouse model 
involves the placement of ultrasound gel over the shaved scalp of an anesthetized mouse (Fig 
3.1). A water chamber is positioned to facilitate propagation of the ultrasound. A central FUS 
transducer is inserted into curved focused ultrasound transducer. Once lambda suture is 
visualized, targeting is achieved via placement of a metal grid with ultrasound-dependent 
detection of the location. Once the ultrasound probe is positioned directly above the lambda 
suture, it is repositioned 1.5mm laterally and 5.5mm anterior. Immediately prior to sonication 
microbubbles are administered via tail vein injection. Focused ultrasound is applied using with a 
spherical single element 1.5 MHz transducer, pulse length (PL) of 10,000 cycles, pulse repetition 
frequency (PRF) of 5 and a peak rarefactional (negative) pressure is 2500 kPa, total duration 60 
seconds[130]. Upon application of the ultrasound beam, circulating microbubbles oscillate and 
implode causing a microjet of fluid and increased local pressure on the blood vessel (Fig 3.1). In 
regions where ultrasound pressures are far above the therapeutic threshold, this causes 

























The experimental setup (A) of the focused ultrasound induced intracerebral hemorrhage method 
(FUS-ICH) involves placemen of ultrasound gel on the shaved head of an anesthetized mouse, 
The focused ultrasound beam travels through chambers of degassed water. The FUS-ICH 
procedure (B) involves targeting the focused ultrasound 5.5 mm anterior and 1.5 mm lateral 
(right) to the lambda suture observed through a shaved scalp. Under the pressure of the 
ultrasound beam injected circulating microbubbles oscillate and rupture sending a micro jet of 
fluid against the vessel wall. This causes vascular rupture and hemorrhage in vessels within the 








3.3: Application of FUS-ICH results in large BBB opening by 1 hour  
Following FUS-ICH at 2.5 MPa (FUS-ICH 2.5), gadolinium enhanced T1 weighted MRI 
of the brain shows a large area of hyperintensity in the target region demonstrating gadolinium 
extravasation through a marked opening of the blood brain barrier (Fig 3.2). This diffuse blood 
brain opening is apparent as early as 1 hour following application of focused ultrasound (Fig 
3.2). Notably, within the region of MRI hyperintensity are numerous hypointense sub-regions 
that correspond to the hemorrhage observed on post-mortem gross specimens (Fig 3.2). Although 
gadolinium is a contrast agent associated with hyperintensity on T1 weighted MRI, high 
concentrations of gadolinium have been observed to paradoxically cause regions of 
hypointensity[151].  
The MRIs conducted on the sham mice were observed to lack both the diffuse 
hyperintensity seen within the sonicated hemisphere of the FUS-ICH brains and the focal regions 
of hypointensity (Fig 3.2). These mice demonstrate an intact blood brain barrier preventing both 
high- and low-level extravasation of gadolinium into the brain parenchyma. These findings are 
consistent among all sham mice in this study providing evidence that the blood brain barrier 
opening, and development of hemorrhage are a direct result of the application of the FUS-ICH 
technique rather than spontaneous development of pathology. Gross specimen slices of brains 









Figure 3.2: Gadolinium enhanced T1 weighted MRI following FUS-ICH 2.5  
 
Serial T1W MRI with gadolineum (A) show no region of hyper-intensity in the brains of sham 
mice (top row). FUS-ICH mice (bottom row) show hypo-intensities within an area of hyper-
intensity at 1-hour post-procedure. Key MRI images (yellow asterisk) shown enlarged (B) next 
to gross specimen images of the corresponding brain collected 24 hours post-procedure. Sham 






3.4: Changes apparent on T2 weighted MRI are dynamic over time  
Evaluation of the T2 weighted MRI at 4 hours post-procedure demonstrates a 
heterogeneous region of hyperintensity within the target region (Fig 3.3). Follow-up evaluation 
of the same brains at 24h post-procedure shows hyperintensity on T2-weighted imaging in 
the corresponding region observed at 4 hours post procedure. The area of hyperintensity at 24 
hours is enlarged compared to that at 4 hours (Fig 3.3). Both blood and edema may appear 
hyperintense on T2 weighted imaging during early timepoints following hemorrhage onset[152].  
Over time the appearance of blood on MRI is anticipated to change with hyperintensity on T2 
during the hyperacute or <24h timeframe with a shift toward hypointensity during the acute 
phase. During the hyperacute phase of FUS-ICH pathology it is difficult to distinguish hematoma 
from surrounding edema on T2 weighted imaging as the entire region shows hyperintensity. 
Gross specimen slices at corresponding locations to the MRI images demonstrate hemorrhage 
within the region of MRI hyperintensity, however the region of hyperintensity extends beyond 
the area of hematoma observable in gross specimens suggesting surrounding edema (Fig 3.3). 
Mice in the sham condition do not show regions of hyperintensity or hypointensity 
corresponding to cerebral edema or hemorrhage. Consistent with the lack of pathology apparent 
on T2 weighted imaging, sham mice show no signs of hemorrhage or edema on serial gross 
specimen slices (Fig 3.3). The gross specimen of the FUS-ICH 2.5 slices show hemorrhage 
through the full path of the ultrasound beam in the target region with a gradual tapering of the 































Serial T2W MRIs (A) of Sham (top row) and FUS-ICH 2.5 at 4 hours (row 2) and 24 hours  
(row 3) post-sonication. Serial gross specimen of FUS-ICH 2.5 + 24 hours (row 4) shows 
hemorrhage. Key sections [asterisk] are represented in (B) with region of hyperintensity outlined 




3.5 Hematoxylin and Eosin (H&E) 
Hemorrhage is apparent on H&E staining at 24 hours post FUS-ICHh 2.5 within the path of the 
ultrasound beam (Fig 3.4). Intact red blood cells can be observed in addition to clot formation. 
There is no apparent red blood cell lysis at this time. The tissue surrounding the hemorrhage does 
not exhibit obvious pathology (Fig 3.4).   













H&E imaging of a brain following FUS-ICH 2.5 at 24 hours post-sonication shows frank 
hemorrhage on the ipsilateral hemisphere. An enlarged image shows focal hematomas without 






3.6: Time course 
The appearance of pathology on T2 weighted MRI is dynamic following the FUS-ICH 
procedure. As noted above, the region of pathology appears as an area of hyperintensity at 4 
hours post-procedure and appears similarly hyperintense but enlarged at 24-hours post-procedure 
(Fig 3.3). The properties of the blood constituting the hemorrhage changes over time resulting in 
distinct appearance on T2 weighted MRI imaging. During the chronic period of hemorrhage, the 
hematoma has been noted to appear hypointense on T2 weighted MRI. At 7 days following the 
FUS-ICH procedure, T2 weighted imaging shows multifocal regions of hypointensity 
representing hemorrhage rather than edema. At this timepoint, minimal hyperintensity is 
observable suggesting the resolution of edema by 7 days post-procedure within this model (Fig 
3.5). Gross specimens collected 4 hours, 24 hours, and 7 days following FUS-ICH 2.5 suggest a 
dynamic hemorrhagic region increasing in size up to 24 hours with near-complete resolution by 7 
days post-sonication (Fig 3.5). A multifocal hemorrhage is observable at 1-hour post FUS-ICH 
2.5. Mice sacrificed 24 hours following the induction of intracerebral hemorrhage also show a 
multifocal hemorrhage but with apparent increases in red blood cell extravasation compared to 4 
hours post-sonication (Fig 3.5).  
The gross specimen collection is post-mortem and therefore does not allow for serial 
observation at distinct time points, however the appearance of the hemorrhagic region is 
consistent within the time points. This taken together with the dynamic size of the pathologic 
area on T2 weighted MRI strongly suggest the induction of a dynamic hematoma following 
FUS-ICH with increase in hematoma burden up to 24 hours post-procedure followed resolution 















T2W MRI (A) of a similar coronal plane of the same FUS-ICH 2.5 -brain followed at 3 
timepoints: 4 hours (left), 24 hours (middle), and 7 days (right) following sonication. Gross 
specimen samples from different brains collected 4 hours (left), 24 hours (middle), and 7 days 
(right) after FUS-ICH 2.5 procedure are shown. 
 
3.7: Focused Ultrasound alone does not induce frank pathology  
Focused ultrasound without microbubbles is capable of inducing changes in the tissue to 
which it is applied. The FUS-ICH model relies on the combination of high-pressure focused 
ultrasound with injected microbubbles. Under the pressure of the ultrasound the microbubbles 
oscillate creating shear stress on the vessels. At high pressures the ultrasound causes the 
microbubbles to become unstable and rupture causing high internal pressure on the walls of the 
blood vessel. It could be possible that the damage seen would arise from the pressure of the 
focused ultrasound and therefore be the result of pressure external to the vasculature rather than 
an internal pressure. To determine whether the focused ultrasound in the absence of circulating 
microbubbles is capable of inducing hemorrhage and damage when applied at the pressures used 
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for the FUS-ICH technique mice were subjected to the high pressure, 2.5 MPa, focused 
ultrasound in the absence of circulating microbubbles. Mice in the focused ultrasound only 
(FUSO) condition show no hyperintensity on T1 weighted MRI demonstrating a lack of blood 
brain barrier opening in the absence of circulating microbubbles (Fig 3.6). Gross specimens of 
the brains collected 24 hours following sonication show no hemorrhage (Fig 3.6). The lack of 
hemorrhage and blood brain barrier opening show that in the absence of microbubbles the 
focused ultrasound at 2.5 MPa does not induce the damage seen in the FUS-ICH condition. 
Considering this, the insult in the FUS-ICH condition is the result of the interaction between the 
microbubbles the focused ultrasound beam and the vasculature.  









Serial T1W MRI images (A) of FUS O brains show no blood brain barrier opening. Serial Slices 
(B) of the same brain show no hemorrhage.  
 
3.8 Behavioral Analysis 
As the presence of lateral motor deficits is a key feature of striatal intracranial 
hemorrhage in humans, we employed behavioral testing to probe the presence of unilateral motor 
deficits in mice following FUS-ICH. Numerous testing modalities exist to analyze the behavior 
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of rodents in pathological conditions. A combination of a set of assays can create a reliable 
description of the overall neurological function of mice following insults such as stroke. The 
neuroscore is a multifactor assay of neurologic function often including categories such as 
general appearance and motility is a well-characterized neurofunctional assessment tool. 
Multiple distinct category combinations and scoring methods have been applied to assess the 
physiologic impact of neurologic disease in rodents. A 28-point neuroscore assesses many 
features including wire hang, grip strength, the righting reflex, and the contralateral reflex. 
Within this scoring system a mouse with no pathology would be expected to receive a score of 
28 points whereas 0 points represents severe impairment. The studies presented here employ a 
restricted set of the 28-point neuroscore criteria tailored to deficits expected from a unilateral 
intracerebral hemorrhage. Categories included general appearance with a maximum score of 3, 
circling with a maximum score of 4, and motility with a maximum score of 3 are combined into 
a neuroscore with a maximum score of 10. In this 10-point neuroscore system, a score of 0 
represents a severely impaired mouse and a score of 10 suggests no deficit. 
Mice in the sham condition consistently scored 10 demonstrating no deficits in motility 
or general condition both on pre-procedure testing and on 24-hour follow-up (Fig 3.7). On pre-
procedure testing, mice in the FUS-ICH 2.5 condition also scored consistently in the normal 
range with only one mouse scoring below a 10 (Fig 3.7). At 24 hours following induction of 
FUS-ICH, mice exhibit a variety of neuroscore results demonstrating a range of physical deficits 
(3.7). Mice show circling behavior, decreased motility, and changes in their overall appearance 
including adopting a hunched posture and decreased grooming.  
Analysis of unilateral striatal damage is aided by the use of the corner turn test. The 
corner turn test assays the sensorimotor function of mice. Mice exhibiting a unilateral striatal 
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injury have been shown to develop a turning bias ipsilateral to the injury. This ipsilateral turning 
preference is due to weakness of the contralateral limbs impairing the mouse’s ability to 
successfully complete turns in the contralateral direction. This assay is quite sensitive, capable of 
detecting a unilateral motor deficit in a mouse that appears otherwise unimpaired. Pre-procedure 
testing shows no bias in turning direction for both sham and FUS-ICH 2.5 mice (Fig 3.7). Sham 
mice continue to show no turning bias at 24-hour post-procedure testing. Mice in the FUS-ICH 
2.5 group are found to demonstrate a strong ipsilateral turning bias at 24 hours post-procedure 
(Fig 3.7). FUSO mice were also assayed within the corner turn test apparatus to determine the 
presence of functional deficits despite the lack of blood brain barrier disruption and hemorrhage 
found in this condition. At baseline, these mice show no turning bias similar to the pre-procedure 
testing of the sham and FUS-ICH 2.5 conditions (Fig 3.7). Mice in the FUSO group 
demonstrated no turning bias compared to their pre-sonication corner turn test trials (Fig 3.7). 
The results of this group are similar to that of the sham mice that have undergone no focused 
ultrasound procedure. In absence of microbubbles the functional pathology, seen in FUS-ICH 2.5 
mice as behavioral deficits in corner turn testing, are not induced.    
3.9 Female mice show a more variable response to FUS-ICH 
Female humans as well as mice have been shown to be less effected by intracerebral 
hemorrhage than males. However, females do experience intracerebral hemorrhage with 
substantial morbidity and mortality. For this reason, it is essential to be able to study the potential 
differential effects of therapeutic interventions in males and females. We set out to compare the 
intracerebral hemorrhage induced via the FUS-ICH method in male and female mice. T1 
weighted MRI imaging of the brain following FUS-ICH 2.5 in female mice shows a diffuse 
region of hyperintensity within the target hemisphere with focal hypointensities as is seen in 
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male mice although with a possible reduction in volume (Fig 3.8). T2 weighted MRI imaging 
shows focal hyperintensity at both 4- and 24-hours post-sonication (Fig 3.8).   
















Neuroscore (A) comparison of Sham and FUS-ICH 2.5. Corner Turn Test Conglomerate (B) 
results for sham, FUS-ICH 2.5, and FUSO, Individual corner turn test results (C) are shown for 
sham FUS-ICH 2.5, and FUSO. 
 
Behavioral testing shows a more variable functional response to focused ultrasound-
induced intracerebral hemorrhage in females compared to males (Fig 3.8). Pre sonication corner 
turn testing shows no turning bias in either males or females (Fig 3.8). Corner turn test analysis 
shows no ipsilateral turning bias in females at either 24 hours or 7 days post-sonication (Fig 3.8). 
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Males in this cohort show an increase in ipsilateral turning preference by 7 days post-sonication 
(Fig 3.8).    




















Serial T1W MRI (A) show diffuse hyperintensity and focal hypointensities with quantification 
(D). Serial T2W MRI (B) at 4 hours (top) and 24 hours (bottom) post sonication show 
hyperintensity in the ultrasound path. Gross specimen serial sections (C) show robust a 
multifocal hemorrhage. Corner turn test results (E) and Neuroscore (F) suggest differing 























Gross specimens show induction of a multifocal hemorrhage in the target region similar to that 
seen in males (Fig 3.8). Female mice do not show any apparent differences in hemorrhage 
induction following FUS-ICH 2.5 compared to males. Gross specimens show induction of a 
multifocal hemorrhage in the target region similar to that seen in males (Fig 3.8). Female mice 
do not show any apparent differences in hemorrhage induction following FUS-ICH 2.5 
compared to males.   
Using a 10-point neuroscore assessing levels of circling, motility, and general appearance 
also demonstrates a differential response to FUS-ICH in male and female mice. The female mice 
in this study show little to no deficits on the neuroscore whereas the male mice show a wide 
range of responses from unaffected to severely impacted (Fig 3.8).  
3.10 Conclusions 
The FUS-ICH technique able to generate a consistently reproducible intracerebral 
hemorrhage within the target region. Along the path of the ultrasound beam, vessels 
experiencing pressure above the pathologic threshold in combination with circulating 
microbubbles exhibit hemorrhage causing a multifocal hematoma involving multiple blood 
vessels. The hemorrhage is appreciable on both T1 and T2 weighted MRI imaging and evolves 
over time. The pathology induced by FUS-ICH is not replicated by application of focused 
ultrasound in the absence of injected microbubbles. The FUS-ICH technique induces a 
symptomatic intracerebral hemorrhage consistent with unilateral striatal injury. Female mice also 
show blood brain barrier opening and development of a multifocal hematoma following the 
FUS-ICH procedure however the behavioral response is more variable than the males and lateral 




Chapter 4: FUS-ICH 2.5 Induces Cellular Responses Relevant to Intracerebral 
Hemorrhage 
4.1 Inflammation 
Inflammation is a prominent feature of neurological pathology[26, 62, 103]. In the 
presence of infectious processes or physical damage within the brain microglia and astrocytes 
mount a robust response[62, 85]. These responses also have a role in intracerebral hemorrhage 
pathology[26, 153]. Following blood-brain barrier disruption, the parenchymal environment is 
exposed to circulating immunogens that are typically shielded from brain tissues. Additionally, 
the blood comprising the hematoma has been found to induce neurotoxicity warranting a rapid 
response from the body in efforts to reestablish homeostasis[26].  
Various pharmacological agents targeting inflammatory pathways are under investigation 
for intracerebral hemorrhage[49, 83]. As this component of intracerebral hemorrhage 
pathophysiology has implications for ongoing investigation in the field and the development of 
therapeutic agents, we set out to understand the presence and timing of inflammatory changes 
following FUS-ICH.   
4.1.1 Morphologic changes in Iba1 following FUS-ICH 2.5 
The FUS-ICH 2.5 model induces alterations in the morphology of microglia within the 
region of the hemorrhage compared to the sham condition (Fig 4.1). Immunofluorescence with 
Iba1 reveals an enlarged cell body and hypertrophied processes in the striatum at 24 hours 
following FUS-ICH 2.5 (Fig 4.1). Mice in the FUSO condition do not show similar changes in 
microglial morphology along the path of the ultrasound beam. The FUSO condition shows 
decreased signal intensity of Iba1 immunofluorescence (Fig 4.1). Some Iba1 can be appreciated 
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and shows microglia with thin processes resembling the morphology of ramified microglia (Fig 
4.1). 













Iba1 immunofluorescence at 40x (Top) scale bar =100 microns. Yellow rectangles represent 
boundaries of zoomed images (bottom) scale bar =10 microns.  
 
The timing of the onset of inflammatory changes is critical to the potential for targeting 
these pathways for pharmacologic intervention. Investigation of the timing of the induction of 
morphological changes within the microglia following FUS-ICH 2.5 demonstrate hematoma 
associated microglia at 1-hour post-sonication (Fig 4.2). At this timepoint the microglial 
morphology remains ramified with multiple branched thin processes emanating from a small cell 
body (Fig 4.2). At 4 hours following FUS-ICH 2.5 perihematomal Iba1 immunofluorescence 
shows fewer microglia processes and increased process thickness (Fig 4.2). Some microglia that 
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appear ramified are also present at this timepoint. As described above, microglia at 24 hours post 
FUS-ICH 2.5 show larger cell bodies with few hypertrophic processes (Fig 4.1). Striatal Iba1 
immunofluorescence at 3 days post-sonication also shows hypertrophic microglial morphology 
suggesting a continued inflammatory response at this timepoint (Fig 4.2). Iba1 is not specific for 
microglia as macrophages are also labeled with Iba1. During homeostasis, microglia can be 
distinguished from macrophages morphologically as macrophages do not show microglia-like 
processes. However activated microglia have been shown to adopt an amoeboid morphology 
with retraction of processes. Therefore, the appearance of Iba1 positive cells with a large cell 
body and amoeboid phenotype could represent either a morphologic change in microglia or the 
appearance of macrophages.  







Scale bar is 100 microns, white outline represents region of hemorrhage 
Iba1 immunofluorescence at 40x scale bar =100 microns. The white outline represents the 
boundaries of a hematoma.  
 
4.1.2 Results 2: CD 68 is increased in FUS-ICH 2.5 condition up to 3 days 
CD68 is utilized as a marker of the phagocytic activity of microglia and macrophages. As 
such, CD68 functions as a readout of microglial activation. CD68 is a glycoprotein localized to 
the membranes of lysosomes within microglia and macrophages. It is a member of the lysosomal 
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associated membrane protein (LAMP) family. The functional role of CD68 within cells is a 
current area of investigation. 



















CD68 immunofluorescence (A) at 40x (top) Scale bar =100 microns, pink rectangles represent 
the boundaries of the zoomed images (bottom) Scale bar = 10 microns. Quantification of CD68 
area (B) shows an increase in CD68 in the FUS-ICH 2.5 condition.  
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Homeostatic microglia exhibit a basal level of CD68 positivity with sparse puncta 
observable within the sham condition. There is an increase in CD68 Following FUS-ICH 2.5 
within the striatum at 24 hours post-sonication (Fig 4.3). The puncta of CD68 are densely 
localized within the FUS-ICH 2.5 condition showing high perinuclear staining intensity. The 
focused ultrasound only condition does not induce an increase in CD68 within the targeted 
region of striatum. Intriguingly, the FUSO condition shows less CD68 positivity than the sham 
condition (Fig 4.3).  
 












Western blot of medial right hemisphere with CD68 shows a band at approximately 40 KDa with 
no difference in CD68 protein levels between sham FUSO-ICH and FUSO groups. (left). The 





Western blot analysis of the medial half of the right hemisphere including the cortex and 
striatum, reveal no appreciable differences in CD68 protein levels between the Sham, FUS-ICH 
2.5 + 24 hours, and FUSO conditions (Fig 4.4). Although an increase in CD68 is readily 
appreciated on immunofluorescence imaging of the striatum, these changes may not be sufficient 
to be appreciated on western blot analysis of the full medial portion of the right hemisphere. 
Immunofluorescence analysis of CD68 in the FUS-ICH 2.5 condition was employed at 
distinct timepoints: 1 hour, 4 hours, and 3 days post-sonication. As noted above a profound 
difference in both the localization and the intensity of CD68 positivity are observed at 24 hours 
following FUS-ICH 2.5. Assessment of the timing of the onset of these changes and evaluation 
for resolution of the pathologic phenotype provide an understanding of the progression of 
inflammation within these mice. At 1-hour post-sonication, puncta of CD68 positivity are 
observed in an even distribution among microglial processes and cell bodies. CD68 staining 
intensity appears increased at 4 hours post-sonication however the distribution of the CD68 
puncta remains even between the cell bodies and processes (Fig 4.5). A microglia-like 
morphology can be appreciated within the CD68 immunofluorescence at 1 hour and 4 hours post 
FUS-ICH 2.5 (Fig 4.5). The FUS-ICH 2.5 condition at 3 days following hemorrhagic induction 
show a marked change in the apparent localization of CD68 puncta in the perihematomal region. 
Intense signal positivity of CD68 is observed within the cell body with very few puncta in 
processes (Fig 4.5). This change in localization could indicate an alteration in the morphology of 
the cells present with microglia potentially retracting processes or it may represent CD68 within 
macrophages entering the region. Alternatively, the localization of CD68 may be altered with a 
















CD68 immunofluorescence at 40x (Top) scale bar =100 microns. Pink rectangles represent the 
boundaries of the zoomed images (bottom) scale bar =10 microns.  
 
4.1.3 Results 3: Astrocytes show dynamic response to FUS-ICH 2.5 
Astrocytes have been shown to be involved in the pathophysiology of various 
neurological conditions. As both a critical component of the blood-brain barrier, and a 
contributor to neuroinflammation, examination of the role of astrocytes in intracerebral 
hemorrhage is of particular interest. Glial Fibrillary Acidic Protein (GFAP) is a well-studied 
astrocyte marker. We employed GFAP immunofluorescence to assay the responses of astrocytes 
to FUS-ICH 2.5. Sham mice show robust GFAP immunofluorescence revealing stellate-shaped 
astrocytes (Fig 4.6). At 24 hours following induction of hemorrhage with FUS-ICH 2.5, GFAP 
immunofluorescence shows lower intensity than in the sham condition. Astrocyte morphology in 
the FUS-ICH 2.5 condition is stellate with substantial arborization (Fig 4.6). The FUSO 
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condition shows similar intensity of GFAP immunofluorescence to the FUS-ICH 2.5 condition. 
Astrocytes of the mice subjected to FUSO show increased linearity with fewer branched 
processes than observed in either the sham or FUS-ICH condition (Fig 4.6).  














GFAP immunofluorescence at 40x (Top) scale bar =100 microns. Pink rectangles represent the 
boundaries of the zoomed images (bottom) scale bar =10 microns.  
 
Time course analysis of GFAP at 1 hour, 4 hours, and 3 days following FUS-ICH 
induction reveals a progressive increase in GFAP signal with alterations in morphology (Fig 
4.7). At 1 hour following FUS-ICH very little GFAP positivity is observable within the 
perihematomal region (Fig 4.7). By 4 hours post-sonication there is an increase in GFAP signal 
intensity compared to 1-hour post-procedure. Astrocytes with few processes are seen in the 
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perihematomal region. At 3 days post-induction of hemorrhage, there is a robust increase in 
GFAP signal intensity (Fig 4.7). Astrocyte processes appear hypertrophic. There appears to be a 
dynamic astrocyte response to FUS-ICH 
Figure 4.7: Perihematomal GFAP is low at 1-hour post FUS-ICH with profound increase 








GFAP immunofluorescence at 40x scale bar =100 microns. The white outline represents the 
boundaries of a hematoma.  
 
4.2 Cell death 
4.2.1 The presence of cell death in FUS-ICH 2.5 is shown with TUNEL 
Cell death is a critical factor of intracerebral hemorrhage pathology. TUNEL, (Terminal dUTP 
Nick End Labeling) is a marker of DNA fragmentation that occurs during cell death. TUNEL 
assays were employed to assess the presence of cell death within the FUS-ICH 2.5 condition. 
The TUNEL assay reveals cell death in the FUS-ICH 2.5 condition at 24 hours post procedure in 























TUNEL labeling (right) in Sham (top) and FUS-ICH (bottom) show clusters of TUNEL 
positivity in FUS-ICH 2.5 + 24h. Co-stain with Hoechst (left) show nuclei within TUNEL 
positive Clusters (pink rectangles). Scale bar = 100 microns. 
 
Markers of various cell death pathways 
The evaluation of cell death pathways is an active and evolving area of study. Numerous distinct 
pathways to cell death have been discovered and are implicated in neurologic disease including 
apoptosis, necroptosis, and ferroptosis. To assess the possible contribution of the apoptotic and 
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necroptotic pathway to the cell death seen in the FUS-ICH 2.5 group, western blot analysis was 
employed probing components of distinct cell death pathways. Cleaved caspase 3 (cl casp 3) and 
phosphorylated MLKL (pMLKL) are used to assess the possibility of apoptosis and necroptosis 
following FUS-ICH 2.5. Cleaved caspase 3 originally believed to primarily function to induce 
cell death is now appreciated as having varied functions. The presence of cleaved caspase 3 
would support the possibility of involvement of apoptosis in the FUS-ICH induced cell death but 
would not confirm this to be the case. All brains assayed show the presence of both pMLKL and 
cl casp 3 (Fig 4.9). Involvement of apoptosis and necroptosis are a possibility within this system, 
but further investigation will be necessary to determine the contribution of these pathways to 
FUS-ICH 2.5 induced cell death.  










Western blot of medial right hemisphere with cl casp 3 and pMLKL show bands at 
approximately 20 KDa and 40 KDa respectively. Both cl Casp3 and pMLKL are observed in all 






The FUS-ICH 2.5 method induces inflammation and cell death. The neuroinflammatory response 
to FUS-ICH includes morphologic changes in astrocytes and microglia are consistent with 
inflammatory activation. Microglia also show increased levels of CD68 following FUS-ICH 
observable by immunofluorescence. These changes are increased up to 3 days following 
hemorrhagic induction. Cell death is also present following FUS-ICH. Western blotting shows 
the presence of proteins associated with apoptosis and necroptosis, cl casp 3 and pMLKL 
respectively, however no conclusions can be drawn at this point as to whether cell death in the 
FUS-ICH condition is due to either of these pathways. Assessment of the FUSO condition does 
not reveal the same changes in astrocyte or microglia morphology as the FUS-ICH condition. 
Notably the intensity of immunofluorescence in the FUSO condition is below that seen in sham 
mice for both CD68 and Iba1. This suggest that the focused ultrasound alone does impact tissue 










Chapter 5: FUS-ICH 1.5 MPa 
5.1 Introduction 
The parameters used during the application of focused ultrasound determine the resulting 
effects. Pressure, pulse length, and frequency have all been reported to cause varying outcomes 
when the parameter is altered[124, 125, 143, 154]. As pressure is the key parameter of interest in 
the FUS-ICH model considering the believed pressure dependency in human intracerebral 
hemorrhage pathology, varying the pressure applied for the FUS-ICH technique is of interest. 
Previous reports studying the safety of focused ultrasound for therapeutic purposes have 
determined that at high pressures focused ultrasound induces extravasation of red blood cells into 
the parenchyma[130]. The size of the extravasation has been found to be altered with changes in 
the pressure applied during sonication.  
Human intracerebral hemorrhage pathology shows wide variability from asymptomatic 
cerebral microbleeds to debilitating hemorrhagic stroke[20, 51]. Clinically, cerebral microbleeds 
are often discovered incidentally on imaging as patients generally lack symptoms that would lead 
them to seek treatment. The pathophysiology is believed to involve high intravascular pressure as 
hypertension is a critical risk factor of cerebral microbleed development. Asymptomatic 
intracerebral hemorrhage is found in numerous neurological conditions including dementia and 
may be a predisposing factor for a large intracerebral hemorrhage or hemorrhagic stroke. 
Understanding of the contribution of asymptomatic intracerebral hemorrhage to the 
pathophysiology of other neurologic conditions remains incomplete. There exists a limited 
ability to model asymptomatic intracerebral hemorrhage. All of this together poses a particular 
need for the development of inducible mouse models of asymptomatic intracerebral hemorrhage 
involving high intravascular pressures. 
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5.2: BBB opening and Hematoma on MRI 
Application of the FUS-ICH technique with the same parameters previously described for 
the induction of symptomatic intracerebral hemorrhage with the exception of a reduction of the 
peak rarefactional (negative) pressure to 1.5 MPa instead of 2.5 MPa results in blood brain 
barrier opening and the development of intracerebral hemorrhage (Fig 5.1, Fig 5.2)). Gadolinium 
enhanced T1 weighted MRI imaging shows a large, diffuse region of blood-brain barrier opening 
(Fig 5.1). Similar to FUS-ICH at 2.5 MPa, FUS-ICH induced at 1.5MPa shows focal regions of 
hypointensity within the diffuse hyperintensity corresponding to areas of substantial blood-brain 
barrier opening and hemorrhage (Fig 5.1). At 3 days post-sonication the same brains show a 
substantial reduction in the area of hyperintensity compared to that seen at 24 hours post-
procedure. Only a focal hyperintensity along the path of the focused ultrasound beam is visible at 
3 days following the FUS-ICH 1.5 procedure (Fig 5.1).   
T2 weighted imaging at 24 hours following FUS-ICH 1.5 shows a focal region of 
hyperintensity corresponding to the reported appearance of acute hemorrhage with this imaging 
sequence (Fig 5.1). At 3 days following FUS-ICH 1.5 T2 weighted imaging appears similar to 
imaging conducted at 24 hours post-procedure. There is no apparent enlargement or reduction in 
the size of the hyperintensity seen on T2 weighted MRI at 3 days compared to 24 hours post-



























Serial T1W MRI at 1 hour post FUS-ICH 1.5 (Row 1) show diffuse hyperintensity and focal 
hypointensities. At 3 days post sonication T1W MRI (Row 2) shows focal hyperintensities.  
Serial T2W MRI at 24 hours (Row 3) shows focal hyperintensity similar to T2W MRI at 3 days 






5.3 Hemorrhage is visible on gross specimen slices 
Following FUS-ICH 1.5, mice show the development of multifocal intracerebral 
hemorrhage within the focal region of the ultrasound beam (Fig 5.2). Consistent with reports of 
hemorrhage varying with pressure of focused ultrasound, the volume of brain impacted by the 
hemorrhage appears smaller in the FUS-ICH 1.5 condition compared to FUS-ICH 2.5. Similar to 
the FUS-ICH 2.5 condition, the FUS-ICH 1.5MPa procedure induces a dynamic hemorrhage 
with near resolution of the hematoma by 7 days post-procedure (Fig 5.2). At 4 hours following 
induction of intracerebral hemorrhage within the FUS-ICH 1.5 model, circular foci of 
hemorrhage along the path of the focused ultrasound beam are observed (Fig 5.2). FUS-ICH 1.5 
shows similar multifocal hemorrhage at 24 hours with an apparent increase in the density of 
hemorrhagic foci within the affected region compared to 4 hours post-sonication. At 3 days post-
sonication brains subjected to FUS-ICH 1.5 show the development of indentation within the 
hemorrhagic region suggestive of cavity formation (Fig 5.2). At 7 days following FUS-ICH 1.5, 
little to no appreciable hemorrhage is observed. A cavity can be observed within the sonicated 
hemisphere suggesting a region of resolved hemorrhage (Fig 5.2).  
5.4: Behavioral analysis shows no significant deficit following FUS-ICH  
To determine the presence of lateral neurological deficit in mice following FUS-ICH 1.5, 
the corner turn test was employed. As a sensitive assay of asymmetric motor function this test is 
capable of elucidating deficits that may not be appreciated on global assays of neurologic 
function. Both sham and FUS-ICH 1.5 mice underwent corner turn testing prior to and at 24 
hours following the FUS-ICH procedure. Mice with no lateral motor or sensory deficit do not 
show a predictable turning bias. Individual mice may show a left turning bias or a right turning 
bias that is subject to change upon repeated testing however in conglomerate unimpaired mice 
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show no directional preference for left or right either before or after sham procedure (Fig 5.3). 
Mice subjected to the FUS-ICH 1.5 MPa procedure show results similar to the sham mice with 
no significant difference in turning bias 24 hours post-procedure compared to the pre-procedure 
results (Fig 5.3).  











Serial sections of gross specimen (A) show a multifocal hematoma. Gross Specimen from of 
different brains at 4 hours, 24 hours, 3 days and 7 days post sonication following FUS-ICH 1.5 
suggest changes in the hematoma over time.  
 
To determine the presence of delayed subtle unilateral deficits the corner turn test was 
applied at multiple timepoints including pre, 24 hours, 48 hours, 3 days, 4 days, 5 days, 6 days, 
and 7 days post procedure. No significant turning bias emerged following repeated corner turn 
testing in the FUS-ICH 1.5MPa condition (Fig 5.3). The mice in the FUS-ICH 1.5 MPa 
condition do show decreased variability in turning preference and higher rates of ipsilateral 
turning at 4-6 days post-procedure compared to the mice in the sham condition, however this 
does not represent a statistically significant difference (Fig 5.3). It appears that the lack of 
60 
 
appreciable symptoms even with sensitive testing remains stable up to a week following FUS-
ICH 1.5.  
 

















Corner turn test pooled results (A) show no difference between sham and FUS-ICH 1.5 (left) 
FUS-ICH mice show no consistent change in directionality of turns at 24 hours post-
sonication compared to pre-testing. Corner turn test daily for 7 days show no development of 





5.5 Inflammation is present 24 hours following FUS-ICH 1.5 
As the resident immune cells of the brain, microglia are vital to the inflammatory 
response of neurologic states including intracerebral hemorrhage. In response to infection or 
pathologic insult, microglia are observed to adapt an altered morphology[72]. Following 
FUS-ICH 1.5 microglia are observed to demonstrate morphologic changes in the region 
surrounding the hemorrhagic foci. Distal to the hemorrhage, microglia are seen to exhibit a 
highly branched morphology with numerous long processes (Fig 5.4). In the hemorrhagic 
region microglia exhibit a morphology with enlarged cell bodies, and increased process 
thickness (Fig 5.4). These are features are associated with microglial activation suggesting a 
neuroinflammatory reaction to FUS-ICH 1.5 near the hemorrhage.   










50 microns scale bar, white outline represents region hematoma 
 
Iba1 immunofluorescence at 40x (Top) scale bar =50 microns. White outline represents the 
boundary of a hematoma. Rectangles represent boundaries of the zoomed images (bottom) 
scale bar =50 microns 
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5.6 No neuron loss is observed in the perihematomal striatum 24 hours following 
FUS-ICH 1.5  
Neurons are vulnerable to neurologic insults with the loss of neurons believed to be a 
contributing factor to neurologic deficits in the setting of pathology. Considering this, we set out 
to determine whether neuron loss is apparent following the FUS-ICH 1.5 procedure. Brains of 
sham and FUS-ICH 1.5 mice were co-labeled with NeuN and Hoechst, markers of neurons and 
cell nuclei respectively. Counting of NeuN positive and Hoechst positive cells revealed no 
difference between the sham and FUS-ICH 1.5 conditions. Neuronal death is not appreciated 
within the FUS-ICH 1.5 model. Hoechst also fails to show a significant decrease in cellular 
density in mice flowing FUS-ICH 1.5 (Fig 5.5). Further assessment with other readouts of cell 
death such as TUNEL will be necessary to gain a full understanding of the presence or absence 




































        Immunofluorescence with NeuN (blue) and Hoechst (gray) at 40x scale bar=100 





FUS-ICH 1.5 induces an asymptomatic intracerebral hemorrhage with low levels of edema and 
substantial hematoma resolution by 7 days post-procedure. Despite the lack of neurological 
deficits on behavioral testing, the brains do show signs of inflammation. This poses the 
possibility to use the FUS-ICH 1.5 model to better understand asymptomatic intracerebral 



















Chapter 6: Conclusions and Future Directions 
 Focused ultrasound has successfully been applied at high pressures in combination with 
circulating microbubbles to reliably produce mouse models of both symptomatic and 
asymptomatic intracerebral hemorrhage. The higher pressure FUS-ICH 2.5 condition 
demonstrates signs consistent with hematoma evolution including initial enlargement and 
subsequent resolution. Edema is appreciable on T2 weighted MRI and motor deficits are 
consistent with unilateral neurological damage to the striatum[155]. Behavioral testing including 
the neurological score and corner turn testing show clear and consistent differences between the 
mice in the FUS-ICH 2.5 condition and the sham or FUSO condition. These features provide the 
possibility of utilizing the FUS-ICH model to test potential therapeutic agents targeting 
intracerebral hemorrhage. Endpoints to determine efficacy of a proposed therapeutic include 
motor function, hematoma size, and time to resolve the hematoma. All of these features are 
present and modifiable within the FUS-ICH model. The primary endpoint for therapeutic 
discovery is functional outcome modeled by behavior as well as survival[156]. This focus has 
been established as the fundamental goal of applying pharmacologic agents to human disease is 
to modify death and disability. Pharmacologic agents have previously been tested in mice with 
the intention to promote resolution of the hematoma or prevent hematoma expansion but have 
failed to show functional benefit in clinical trials to date[47-49]. This raises the possibility that 
the hematoma and the size thereof is not the primary driving factor of neurologic deficits in 
symptomatic intracerebral hemorrhage. Considering this, it is intriguing that the FUS-ICH model 
generates substantial neurological deficit in mice despite not having a large focal hematoma but 
rather multiple dispersed hematomas. This model provides an opportunity to compare distinct 
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features of preclinical models to better understand other contributing factors to neurologic deficit 
in intracerebral hemorrhage.  
Notably, neither the FUS-ICH 1.5 nor FUS-ICH 2.5 models are associated with mortality 
during the timeframe of this study. Mice consistently survived until sacrifice following induction 
of intracerebral hemorrhage. For studies intending to evaluate the pathophysiology of 
parenchymal hemorrhage this poses the benefit of reducing the number of mice needed to 
complete the study as there will be minimal loss due to mortality. The lack of mortality does 
however pose a limitation for studies that intend to utilize survival as an endpoint for evaluation 
of therapeutic efficacy. A limited 2-mouse pilot study with FUS-ICH applied at 3 MPa with all 
other parameters held constant has demonstrated associated mortality and increased morbidity. 
One mouse died within 4 hours of ICH induction while the other mouse survived but was 
completely immobile. The surviving mouse was also unable to support the weight of its body on 
the left side and therefore exhibited an unbalanced posture. Future studies will expand this pilot 
to generate a model of severe intracerebral hemorrhage with mortality.  
The FUS-ICH technique is minimally invasive involving no craniotomy or cranial 
window requiring only removal of the cranial fur to allow visualization of the lambda suture 
through the scalp. This feature of the technique facilitates the ability to apply FUS-ICH to mice 
exhibiting a wide range of pathology. There is little risk of damage from the procedure itself 
therefore it can be applied to any mice capable of tolerating isoflurane anesthesia.   
Intracerebral hemorrhage is correlated to various disease states including hypertension, 
diabetes, dementia[2]. In the case of dementia for example, the FUS-ICH 1.5 model can be 
applied to understand the role of asymptomatic intracerebral hemorrhage in mouse models of 
diseases such as Alzheimer’s. Because the model is minimally invasive, it can be applied to aged 
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transgenic mice with little concern for adverse effects from the experimental setup. This study 
would allow for the evaluation of potential symptomatic exacerbation when intracerebral 
hemorrhage is superimposed on mouse models of Alzheimer’s disease.  
FUS-ICH can be targeted to any region by adjusting the coordinates of the stereotactic 
system. Superficial and deep structures within the brain are all accessible. This allows for the 
evaluation of intracerebral hemorrhage applied to other regions of the brain. There may be 
interest in generating a cerebellar hemorrhage, occipital, motor cortex or other regional 
hemorrhage. All of these regions can be targeted with the FUS-ICH model.  
The hemorrhage induced by both pressures the FUS-ICH technique detailed here shows 
distinct features from existing mouse models of intracerebral hemorrhage. The hematoma 
produced by the FUS-ICH techniques employed here is multifocal within the path of the 
ultrasound beam whereas the commonly used mouse models of intracerebral hemorrhage 
generate a single hematoma. In addition to providing an opportunity for comparison with 
existing models of intracerebral hemorrhage, this model poses a tremendous opportunity for 
investigating cellular and molecular changes in hemorrhage adjacent tissues. 
FUS-ICH 1.5 has been shown to induce an asymptomatic multifocal intracerebral 
hemorrhage that can be utilized to better understand the role neurologic changes that occur 
following asymptomatic hemorrhage as well as explore the ways that intracerebral hemorrhage 
contributes to pathology in the setting of additional underlying disease. Behavioral testing 
demonstrates that the mice following FUS-ICH 1.5 are functionally normal. They show no 
significant ipsilateral turning bias on corner turn testing up to 7 days post induction of 
intracerebral hemorrhage. Currently the inducible model of cerebral microbleed in existence is 
the laser induced model involving creation of a cranial window to allow for 2 photon imaging 
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guided micro vessel laser ablation[60]. This technique reliably produces a highly targeted injury 
affecting a single blood vessel. The technique can be applied to multiple vessels to induce 
additional foci of microhemorrhage[59]. The laser-induced cerebral microhemorrhage technique 
is limited to the cortex by the need for 2 photon imaging. The FUS-ICH 1.5 model poses the 
potential to be a model of multifocal microhemorrhage and can be applied to any target region 
within the brain.  
Males and females have been found to demonstrate differential responses to various 
pathologies. Interestingly differences between males and females are observed in stroke as well 
with females showing relative protection[157]. Mouse models often show similar inconsistencies 
between pathology in males compared to females[29]. Although the female mice subjected to the 
FUS-ICH 2.5 procedure do not show clear protection, there is an increased variability of their 
functional outcomes following intracerebral hemorrhage. Estrogen has been shown to have 
neuroprotective effects in animal models of numerous conditions including ischemic stroke, 
hemorrhagic stroke, and Alzheimer’s disease[29, 158, 159]. The female mice subjected to FUS-
ICH were housed together for at least 2 weeks to synchronize their estrus cycles[160]. The 
increased variability seen in the behavioral outcomes of female mice may represent persistent 
hormonal differences between the mice. This method of estrus synchronization is not exact and 
given results showing the protective effect of estrogen, varied estrogen levels within the cohort 
would be expected to generate variable neurologic outcomes. Future experiments will evaluate 
the phase of estrus of the female mice individually and stratify results accordingly.  
The focused ultrasound alone condition was included to understand the effects of 
application of the high pressures of the ultrasound beam to the structures of the brain. It could be 
proposed that the effects seen within the FUS-ICH models are the result of high mechanical 
69 
 
pressure of the ultrasound rather than the interaction between the microbubbles and the 
ultrasound resulting in increased intravascular pressure and vessel rupture. It is also possible that 
even in the absence of blood brain barrier opening and hemorrhage that the focused ultrasound 
alone would be sufficient to cause behavioral changes. For these reasons it was critical to include 
a focused ultrasound only condition to better understand the contribution of the individual 
elements of the FUS-ICH procedure to observed pathology. The FUSO condition resulted in no 
blood brain barrier opening or extravasation of red blood cells appreciable by MRI or gross 
specimen evaluation. Brains subjected to the FUSO condition showed no apparent gross 
pathology. Behavioral testing revealed no motor deficits with mice exhibiting normal turning 
preference on the corner turn test. Additionally, mice in the FUSO condition lacked cell 
induction of inflammatory changes. Taken together these findings support a requirement for the 
intravascular microbubbles for the focused ultrasound to result in the observed pathology of the 
FUS-ICH model. 
MRI imaging of hemorrhage is complicated by the varied appearance of hemorrhage 
depending on the characteristics of the blood and the latency to image following the induction of 
hemorrhage[161]. Computed Tomography is a popular imaging modality for appreciation of 
intracerebral hemorrhage in humans[2]. Of particular utility is contrast enhanced CT imaging 
which has the ability to predict hematoma expansion using the spot sign[12]. The spot sign is a 
focal region of hyperdensity within the area of hemorrhage representing extravasation of contrast 
material thus indicating the possibility of continued hematoma growth. It is possible that the 
paradoxical hypointensities seen on gadolinium enhanced T1 weighted MRI following FUS-ICH 
represents a signal similar to the spot sign on contrast enhanced CT. These studies demonstrate a 
region of hypointensity within a diffuse area of hyperintensity. The diffuse hyperintensity is the 
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expected result in the presence of widespread blood brain barrier opening. Hypointensity has 
been observed in the presence of high concentrations of gadolinium[151]. High level gadolinium 
extravasation from the ruptured blood vessels may account the paradoxical hypointense signal. 
This interpretation is supported by the gross specimen slices demonstrating hemorrhagic foci 
corresponding to the regions of T1W MRI hypointensities.  
The FUS-ICH model will join numerous mouse models of cerebrovascular disease 
including the models of inducible and spontaneous intracerebral hemorrhage and 
microhemorrhage as well as models of ischemic stroke[55, 59, 162]. The FUS-ICH 2.5 model 
shares key features seen in the other models of cerebrovascular disease including motor 
impairment, inflammation, cell death, and differential outcomes in male compared to female 
mice. The comparison of models of ischemic mice with models of intracerebral hemorrhage will 
help elucidate common key pathways in the pathophysiology of cerebrovascular disease.    
6.1 Future studies of inflammation 
The inflammatory changes observed following induction of FUS-ICH demonstrate a 
perturbation of microglia as a component of the pathophysiology. The morphological changes 
observed in microglia in both the FUS-ICH 1.5 MPa in addition to the increase in the lysosomal 
protein CD68 found in microglia and macrophages suggest a role for microglial activation 
following FUS-ICH. Determination of the presence of activated microglia will be further probed 
using RNA sequencing. Various studies have carefully detailed changes that are observed 
following pathology[64, 65, 69, 70]. For this reason, it will be useful to identify the presence of 
sequences to understand the specific changes occurring in the microglia following FUS-ICH. It 
will also be intriguing to compare the microglial RNA changes in the FUS-ICH 1.5 model and 
the FUS-ICH 2.5 model. Morphologically the two models produce distinct changes in microglia. 
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It is reasonable to propose that the RNA sequencing for these conditions may result in distinct 
populations of microglia.  
The role of microglia in neurologic injury is a topic of continuous debate. There is 
uncertainty as to whether the microglia offer benefit or worsen pathology. Some suggest benefit 
in the acute setting with a transformation to pathologic prolonged inflammation in chronic 
disease[163]. Evidence to support each side of this discussion have been reported. Microglia are 
tasked with clearing debris and dead cells which is expected to be beneficial in neurologic 
disease however they have the capacity to release cytokines and promote prolonged 
inflammation which may be detrimental to the cells in the surrounding region. Future studies will 
evaluate the role of microglia in the FUS-ICH model. Caspase 8 has been reported to be required 
for microglial activation. We have an inducible conditional microglia specific caspase 8 
knockout mouse line that will be utilized to explore the differences in response to the FUS-ICH 
procedure in mice lacking microglial caspase 8. Preliminary studies with these mice suggest a 
reduction in the size of the overall hemorrhage in caspase 8 knockout mice compared to controls. 
Further investigation will determine the necessity of caspase 8 for microglial changes associated 
with the FUS-ICH procedure.  
6.2 Future studies of cell death 
These studies demonstrated the presence of cell death following FUS-ICH 2.5 shown by the 
presence of TUNEL positive cells within the region of the hemorrhage. Further assessment of the 
cell death will be beneficial to the understanding of intracerebral hemorrhage pathophysiology. 
Various types of cell death have been associated with intracerebral hemorrhage[92, 101, 106]. 
The involvement of distinct cell death pathways will be assayed. Ferrostatin-1 and deferoxamine, 
inhibitors of ferroptosis, have been shown to decrease death of cultured neurons following 
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hemoglobin exposure[101]. Considering the involvement of iron and reactive oxygen species, 
there is particular interest in assaying the presence of cell death via ferroptosis in the FUS-ICH 
system. Currently there are no specific markers of ferroptosis so future studies will assay the 
possibility of this form of cell death as well as study the effects of ferroptosis prevention on 
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Apendix 1: FUS-ICH 2.5 in Microglial Caspase 8 KO mice 
The FUS-ICH model shows alterations in microglial morphology and CD68 content suggestive 
of microglial activation. Therapeutics that interfere with microglial activation have shown 
promise in preclinical models of intracerebral hemorrhage[49, 83]. Caspase-8 has been reported 
to play a pivotal role in microglial activation through a caspase-3 and -7 dependent pathway[76].  
To determine whether caspase-8 is required for microglial activation in response to FUS-ICH as 
well as to determine the role of microglial caspase-8 in FUS-ICH pathophysiology, we subjected 
inducible microglia-specific caspase-8 KO mice and caspase-8 floxed littermates lacking the 
microglial Cre to FUS-ICH at 2.5 MPa. Preliminary results suggest a decrease in the size of the 
hematoma in mice lacking microglial caspase-8 compared to caspase-8 competent littermates 
(Fig A1).  
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These results pose an intriguing potential for targeting caspase-8 to modulate intracerebral 
hemorrhage, however substantial additional investigation will be required to determine whether 
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there is true protection in the microglial caspase-8 condition and to determine the involved 
mechanism if protection is discovered.  
 
 
 
 
